生物技术与制药领域的最新动态
A Swiss company bought Genentech's Vacaville plant — here's how it's going so far - San Francisco Business Times - The Business Journals
Lonza tops core profit forecast driven by main drug manufacturing business - Reuters
CDMO pulse check: Lonza posts major sales rebound as Samsung Bio keeps revenue growth rolling - Fierce Pharma
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing - Pharmaceutical Technology
Lonza leaders on manufacturing readiness: Meeting the cell and gene therapy challenge - BioSpectrum Asia
Strategic planning in ADC development: insights from Lonza - Drug Target Review
Lonza chooses TRU Global Solutions for cleanroom services - Cleanroom Technology
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer - Contract Pharma
Earnings call transcript: Lonza Confirms Strong 2025 Outlook in Q1 2025 - Investing.com
Lonza Group Ag (LZAGY) is a Great Momentum Stock: Should You Buy? - Nasdaq
Inside Lonza CHI’s Innovation Strategy: Future-Ready Capsules for Complex Drugs - PharmTech.com
Ethris and Lonza focus on mRNA respiratory condition vaccines - Pharmaceutical Technology
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention - BioSpace
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines - Contract Pharma
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention - GEN - Genetic Engineering and Biotechnology News
Catching up with Lonza Capsules and Health Ingredients - Nutritional Outlook
Lonza Investing in Large-Scale Biomanufacturing, Bioconjugation, Drug-Product Manufacturing - DCAT Value Chain Insights
Lonza Implements Streamlined Operating Model - Contract Pharma
Lonza Leadership Visits UNH's Tissue Culture Lab - University of New Hampshire
Exogenus Therapeutics Chooses Lonza to Manufacture Exo-101 - Contract Pharma